Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
VALIUM (diazepam) is a classic benzodiazepine administered via injection for rapid anxiolysis, muscle relaxation, and seizure management. It crosses the blood-brain barrier quickly to modulate GABA neurotransmission, producing sedative and anticonvulsant effects. The injectable formulation is used in acute care and perioperative settings where rapid onset is critical.
A legacy injectable benzodiazepine with moderate competitive pressure (30%) approaching loss of exclusivity; brand team likely focused on cost management and institutional relationships rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on VALIUM offers limited growth opportunity but strong institutional knowledge value; roles focus on maintaining market share, managing price erosion, and ensuring reliable supply in acute care settings. This is a career position suited to operations, relationships, and cost management rather than brand building or clinical innovation.
Worked on VALIUM at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.